Efficacy and safety of TACE combined with ablation and regorafenib for unresectable hepatocellular carcinoma: A real-world study.

被引：0

作者：

Xiong, Yiqi ^{[1
]}

Gao, WenFeng ^{[1
]}

Long, Jiang ^{[1
]}

Hu, CaiXia ^{[1
]}

Yuan, ChunWang ^{[1
]}

Sun, Yu ^{[1
]}

Shi, QinSheng ^{[1
]}

Sun, Bin ^{[1
]}

Zhang, YingHua ^{[1
]}

Cui, XiongWei ^{[1
]}

Hao, MeiJun ^{[1
]}

Li, Jianjun ^{[1
]}

Zhang, Yonghong ^{[1
]}

机构：

[1] Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e16170

引用

页数：1

共 50 条

[1] Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
Han, Yue
Cao, Guang
Sun, Bin
Wang, Jian
Yan, Dong
Xu, Haifeng
Shi, Qinsheng
Liu, Zechuan
Zhi, Weihua
Xu, Liang
Liu, Bojun
Zou, Yinghua
[J]. BMC GASTROENTEROLOGY, 2021, 21 (01)
[2] Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
Yue Han
Guang Cao
Bin Sun
Jian Wang
Dong Yan
Haifeng Xu
Qinsheng Shi
Zechuan Liu
Weihua Zhi
Liang Xu
Bojun Liu
Yinghua Zou
[J]. BMC Gastroenterology, 21
[3] The efficacy and safety of Radiofrequency ablation combined with Lenvatinib plus Sintilimab in Unresectable Hepatocellular Carcinoma: a real-world study
Wang, Xishu
Sun, Ximin
Lei, Yongrong
Fang, Lingyan
Wang, Yuedi
Feng, Kai
Xia, Feng
[J]. BMC CANCER, 2024, 24 (01)
[4] Efficacy and safety of regorafenib alone or in combinations for advanced hepatocellular carcinoma: A multicenter real-world study.
Zhu, Haidong
Zhu, Xiaoli
Song, Yusheng
Wang, Qi
Wu, Jianbing
Xu, Hao
Teng, Gaojun
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16122 - E16122
[5] Efficacy and safety of second-line regorafenib after sorafenib or lenvatinib first line in patients with unresectable hepatocellular carcinoma: A real-world study.
Xue, Feng
Zhai, Jian
Liu, Jianwei
Fu, Zhigang
Sun, Yanfu
Ge, Ruiliang
Bai, Shilei
Li, Xiaowei
Wang, Kui
Qu, Zengqiang
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16125 - E16125
[6] A real-world study of TACE combined with regorafenib as a second-line treatment for advanced hepatocellular carcinoma
Liu, Shaoxing
Gao, Song
Guo, Jianhai
Kou, Fuxin
Zhang, Xin
Liu, Baojiang
Feng, Aiwei
Wang, Xiaodong
Chen, Hui
Zhu, Xu
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[7] Efficacy and safety of radiotherapy combined with regorafenib for advanced hepatocellular carcinoma: A real-world study from a single center
Xin, Lingxia
Wang, Liming
Zhai, Yirui
Wang, Shulian
Tang, Yuan
Liu, Yueping
Song, Yongwen
Fang, Hui
Li, Ning
Qi, Shunan
Lu, Ningning
Li, Ye-Xiong
Chen, Bo
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[8] Real-world efficacy and safety of donafenib-based therapies in patients with unresectable hepatocellular carcinoma: A retrospective study.
Shang, Changzhen
Luo, Xuan
Zhong, Jinyi
Zhang, Jianlong
Li, Huilong
Tan, Wenliang
Lei, Zhang
Chen, Yajin
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[9] Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World
Li, Xiaowei
Fu, Zhigang
Chen, Xiaoxia
Cao, Kunkun
Zhong, Jiaming
Liu, Li
Ding, Ning
Zhang, Xiaoli
Zhai, Jian
Qu, Zengqiang
[J]. FRONTIERS IN ONCOLOGY, 2022, 12
[10] Real-world registry of patients with unresectable hepatocellular carcinoma: The OREIOS study.
Chan, Stephen Lam
Ryu, Min-Hee
Waked, Imam
Shao, Yu Yun
Tai, Wai Meng David
Breder, Valeriy
Alolayan, Ashwaq
Ganguly, Sandip
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS618 - TPS618

← 1 2 3 4 5 →